Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Histamine dihydrochloride to prevent relapse in AML: development and ongoing research

Kristoffer Hellstrand • 1 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Histamine dihydrochloride

Kristoffer Hellstrand, MD, PhD, of Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden, speaks at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Prof. Hellstrand takes us through the development of the NOX2 inhibitor histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia (AML), leading to its approval in 2009, before discussing ongoing work investigating the underlying effects of this therapy.

More from Kristoffer Hellstrand

1:25
Hellstrand lab leukemia research: exploring immune escape and defining therapeutic targets
Kristoffer Hellstrand • 14 Mar 2019
1:22
The importance of finding strategies to prevent relapse of acute myeloid leukemia (AML)
Kristoffer Hellstrand • 19 Feb 2017
1:17
Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML
Kristoffer Hellstrand • 19 Feb 2017

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals